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Gislaine Casanova1,2† and Poli Mara Spritzer1,2,3*†Abstract
Background: Much attention has been drawn to the deleterious effects of adding progestins to estrogen as
hormone therapy (HT) in postmenopausal women. Some widely prescribed progestins have been shown to
partially oppose the beneficial effects of estrogens on surrogate markers of cardiovascular disease (CVD) risk.
Progestins with higher androgenic activity may interfere with lipid profile and glucose tolerance, and could affect
mechanisms of estrogen-induced C-reactive protein (CRP) stimulation. Recent data have shown that norpregnane
derivatives, but not micronized progesterone, increase the risk of venous thromboembolism among transdermal
estrogens users. The aim of the present study was to assess the effects of combining micronized progesterone with
non-oral estrogen therapy on lipid profile and cardiovascular risk factors in a sample of early postmenopausal
women.
Methods: Clinical trial including 40 women receiving intranasal 17β estradiol 3 mg/day for two months and 46
women receiving percutaneous 17β estradiol gel 1.5 mg/day for three months (E2). Both groups received an
additional 200 mg/day of micronized progesterone by vaginal route 14 days/month (E2+P). Outcome measures
included body weight, waist circumference, body mass index (BMI), lipid profile and ultra-sensitive C-reactive
protein (usCRP) at baseline and during the E2 or E2+P portions of treatment.
Results: Mean age was 51±3 years. Mean time since menopause was 22.2±10 months. Most participants were
overweight; HT did not change BMI. E2 and E2+P did not affect waist circumference and weight. Menopausal
symptoms improved after HT. The effects of intranasal and percutaneous estradiol were similar, regardless of the
addition of progesterone. Similarly, for the overall group of 86 women, micronized progesterone did not alter the
response to E2. Blood pressure, glucose, insulin, HDL-c, triglycerides, and usCRP remained constant with or without
micronized progesterone. Total cholesterol decreased after E2, and progesterone maintained this reduction. LDL-c
levels were similar at baseline and with E2, and lower during E2+P in relation to baseline.
Conclusions: Cyclic, short term exposure to vaginal micronized progesterone did not alter the metabolic and
cardiovascular effects of non-oral E2 in early, apparently healthy, postmenopausal women.
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Much attention has been drawn to the deleterious
effects of adding progestins to estrogen as hormone
therapy (HT) in postmenopausal women [1]. Recent
prospective randomized studies have raised great con-
cern regarding this combination, which has been linked
to a negative impact on the cardiovascular and venous
systems and on cognition [2], as well as to the develop-
ment of breast cancer [3] in women in the menopause
transition and postmenopause.
Progestogens encompass both progesterone, the
physiological molecule synthesized and secreted by the
ovary, and synthetic compounds named progestins [4].
All progestins share a progestogenic effect that causes
the endometrium to enter the secretory phase and deter-
mines a decrease in endometrial disease [5]. However,
other biological effects of progestins vary widely, since
each progestin or progestin metabolite binds to specific
steroid receptors. Some of the most widely prescribed
progestins have been shown to partially oppose the
beneficial effects of estrogens on surrogate markers of
cardiovascular disease (CVD) risk [4]. Progestins with
higher androgenic activity may interfere with lipid pro-
file and glucose tolerance [6], and could affect mechan-
isms of estrogen-induced C-reactive protein (CRP)
stimulation [7].
Even though the route of estrogen administration is
known to be an important determinant of cardiovascular
risk in postmenopausal women using HT [8], recent data
have shown that norpregnane derivatives, but not micro-
nized progesterone, increase the risk of venous
thromboembolism among transdermal estrogens users
[9]. A few studies indicate that micronized progesterone
may have a better risk profile with respect to variables
related to cardiovascular risk [10,11]. Therefore, not only
the route of estrogen administration, but also the type of
progestin may be important in determining the overall
benefit-risk ratio for HT.
The aim of the present study was to assess the effects of
combining natural micronized progesterone with non-oral
estrogen therapy on variables related to lipid and hormo-
nal profile and on ultra-sensitive C-reactive protein
(usCRP) in a sample of early postmenopausal women.
Results
The mean age of participants was 51 ± 3 years, and 96%
were Caucasian (the remaining 4% were of mixed African
and European ancestry). Mean age at menopause was
49.4 ± 3 years, and mean time since menopause was 22.2
± 10 months. Thirteen (15%) patients were smokers.
The effects of intranasal and percutaneous gel were
similar during E2 and E2+P (Table 1). Table 2 presents
body mass index (BMI), weight, waist circumference,
blood pressure and Kupperman score for menopausalsymptoms before and during E2 and E2+P in the overall
group of 86 participants. Most participants were over-
weight. BMI did not change with HT. Similarly, waist
circumference, weight and systolic and diastolic blood
pressure remained unchanged during HT with E2 alone
or E2+P. At baseline, all patients presented menopausal
symptoms that improved significantly with treatment, as
shown by the Kupperman score (Table 2).
Table 3 shows metabolic variables and usCRP at base-
line and during treatment for the overall group. Glucose,
insulin, high-density lipoprotein cholesterol (HDL-c), tri-
glycerides, and the high-sensitivity C-reactive protein
test (hsCRP) remained constant after non-oral therapy
with or without micronized progesterone. Total choles-
terol decreased after E2-only treatment, and the addition
of progesterone maintained this reduction. Low-density
lipoprotein cholesterol (LDL-c) levels were similar at
baseline and with E2 only, and were lower during E2+P
treatment in relation to baseline.
Discussion
In the present study, cyclic exposure to vaginally admi-
nistered micronized progesterone over the short term
failed to affect lipid profile in early and apparently
healthy postmenopausal women. Several studies have
evaluated the relationship between estrogen dose and/or
route of administration and cardiovascular benefit-risk
ratio of HT in postmenopausal women. More recently,
observational studies began to draw attention to the im-
pact of using specific types of progestin in combination
with estrogen. However, there is a paucity of data
derived from clinical trials to assess the effect of differ-
ent progestogens on variables related to cardiovascular
risk. Therefore, this work provides an important contri-
bution toward clarifying the impact of combined micro-
nized progesterone plus non-oral estrogen therapy.
Menopause is a risk factor for CVD because of the ensu-
ing endogenous estrogen deficiency, which has a detrimen-
tal effect on cardiovascular function and metabolism. Even
though there are biologically plausible mechanisms of car-
diovascular protection against harm produced by estrogen
therapy, recent clinical trials suggest that estrogen may be
associated with cardiovascular risk rather than benefit in
the postmenopause [12]. However, reanalysis of these stud-
ies has indicated a possible protective window in which re-
cent postmenopausal women in their sixth decade may
benefit from HT [1,13]. In addition, it has been speculated
that the cardioprotective benefits of HT may be more evi-
dent in the early postmenopausal period [14], although this
is a controversial issue [15]. In the present study, the use of
a sample of apparently healthy and relatively young (mean
age of 51.3 ± 3 years) women who were postmenopausal
for less than three years (22.2 ± 10 months) enabled us to
more accurately demonstrate the neutral or beneficial
Table 1 Anthropometric and clinical variables according to type of non-oral estradiol (intranasal or percutaneous gel)
Baseline E2 E2+P P
Intranasal Percutaneous Intranasal Percutaneous Intranasal Percutaneous
n = 40 n = 46 n = 40 n = 46 n = 40 n = 46
BMI 26 ± 3 26 ± 3 26 ± 3 26 ± 3 26 ± 3 26 ± 3 0.6
Weight (kg) 66 ± 7 64 ± 9 66 ± 7 64 ± 9 66 ± 7 64 ± 10 0.6
WC (cm) 84 ± 6 84 ± 8 84 ± 6 84 ± 8 83.5 ± 5 83.6 ± 9 0.6
SBP (mmHg) 118 ± 15 119 ± 12 116 ± 15 114 ± 15 118 ± 14 116 ± 14 0.4
DBP (mmHg) 75 ± 7 77 ± 7 75 ± 9 74 ± 9 76 ± 10 74 ± 10 0.2
Total-c (mg/dL) 222 ± 31a† 211 ± 27a† 212 ± 31b† 201 ± 27b† 205 ± 31b† 200 ± 32b† 0.5
HDL-c (mg/dL) 63 ± 12 63 ± 18 62 ± 14 60 ± 15 63 ± 14 60 ± 16 0.2
LDL-c (mg/dL) 134 ± 28a† 125 ± 29a† 128 ± 32a,b† 118 ± 26a,b† 121 ± 26b† 117 ± 29b† 0.5
Triglycerides (mg/dL) 122 ± 49 117 ± 56 117 ± 48 114 ± 54 108 ± 42 115 ± 62 0.3
Fast glucose (mg/dL) 91 ± 11 92 ± 9 91 ± 8 91 ± 8 93 ± 11 91 ± 10 0.2
2h glucose (mg/dL) 106 ± 29 102 ± 23 113 ± 38 103 ± 35 110 ± 39 101 ± 31 0.2
Insulin (μU/mL) 7 (4–10) 6 (3–9) 6 (2–8) 7 (3–9) 6 (4–9) 7 (3–9) 0.2
Estradiol (pg/mL) 14 (8–17) 11 (5–20) 40 (9–121) 65 (20–119) 47 ( 13–68) 49 (10–96) 0.1
hsCRP (mg/L) 2.1 (0.4-3.9) 1.1 (0.3-2.3) 1.6 (0.5-3) 1.4 (0.2-3) 1.5 (0.5-2) 1 (0.2-2) 0.6
Values expressed as median and interquartile range or mean ± SD. Two-way analysis of variance with repeated measures (non parametric variables were log-converted
for statistical analysis and reconverted for presentation in table format). P = difference between intranasal and percutaneous treatment.
† = P < 0.01 for difference between baseline, E2 and E2+P. Different superscript letters indicate statistical difference with Bonferroni multiple-comparison
correction test (α < 5%).
Baseline: before hormone therapy; E2: estradiol only; E2+P estradiol + micronized progesterone.
Intranasal: 3 mg/day 17β estradiol by intranasal route (n = 40) for two months. Percutaneous: 1.5 mg/day 17β estradiol gel by percutaneous route (n = 53) for
three months.
BMI body mass index, DBP diastolic blood pressure, HDL-c high-density lipoprotein cholesterol, hsCRP high-sensitivity C-reactive protein test, LDL-c low-density
lipoprotein cholesterol, SBP systolic blood pressure, Total-c total lipoprotein cholesterol, WC waist circumference, 2h glucose: glucose levels 2 hours after 75g oral
glucose load.
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ation with micronized progesterone- combined period.
Blood pressure levels remained unchanged after HT in
the present sample. Previous studies have shown that
non-oral estrogen therapy associated with micronized
progesterone had no deleterious effects on blood pres-
sure in normotensive and controlled hypertensive post-
menopausal women [10,16]. Estrogen increases the
release of nitric oxide causing relaxation of smooth
muscle cells and vasodilatation.Table 2 Clinical and anthropometric variables and menopaus
Baseline
BMI 26.3 ± 3
Weight (kg) 65.5 ± 8.3
Waist circumference (cm) 84.3 ± 7.5
Systolic blood pressure 118.6 ± 13.5
Diastolic blood pressure 76.2 ± 7.3
Kupperman score 26 (17–30)a
E2 (pg/mL) 13 (5–19)a
Values expressed as median and interquartile range or mean ± SD. P = two-way analysi
for statistical analysis and reconverted for presentation in table format).
Different superscript letters indicate statistical difference with Bonferroni multiple-c
Baseline: before hormone therapy; E2: estradiol only; E2+P estradiol + micronized p
BMI body mass index.Progestins modulate the effects of estrogen on hepatic
endocrine function through intrinsic androgenic proper-
ties. When co-administered with estrogen, progestogen
may also have significant effects on body composition
and metabolism because of its androgenic properties.
The effects of HT on weight and body composition re-
main controversial [17]. In our study, non-oral E2 ther-
apy with or without micronized progesterone did not
modify waist circumference, BMI or body weight. Add-
itionally, the treatment did not interfere with glucose oral symptoms (n = 86)
E2 E2+P P
26.29 ± 3 26.23 ± 3.1 0.8
65.58 ± 8.3 65.4 ± 8.6 0.7
84.2 ± 7.6 83.5 ± 7.4 0.06
115 ± 14.9 116.7 ± 14.3 0.1
74.7 ± 9.5 74.9 ± 9.7 0.4
6 (0–12.5)b 4 (0–8)b < 0.01
54 (13–122)b 48 (13–80)b < 0.01
s of variance with repeated measures (non parametric variables were log-converted
omparison correction test (α < 5%).
rogesterone.
Table 3 Anthropometric and metabolic variables and
markers of endothelial function (n = 86)
Baseline E2 E2+P P
Total-c (mg/dL) 216 ± 31a 207 ± 30b 203 ± 32b < 0.01
HDL-c (mg/dL) 63 ± 16 61 ± 15 61 ± 15 0.06
LDL-c (mg/dL) 129 ± 29a 123 ± 29a,b 119 ± 28b < 0.01
Triglycerides (mg/dL) 120 ± 53 115 ± 51 111 ± 53 0.2
Fast glucose (mg/dL) 91 ± 11 91 ± 8 92 ± 11 0.2
2h glucose (mg/dL) 103 ± 27 108 ± 36 105 ± 36 0.2
Insulin (μU/mL) 6.9 (3.9-9.7) 6.2 (2.8 -8.8) 6.9 (3.8 -9.1) 0.2
hsCRP (mg/L) 1.51 (0.38-2.9) 1.64 (0.4-3) 1.19 (0.3-2.1) 0.1
Values expressed as median and interquartile range or mean ± SD. P = two-
way analysis of variance with repeated measures (non parametric variables
were log-converted for statistical analysis and reconverted for presentation in
table format).
Different superscript letters indicate statistical difference with Bonferroni
multiple-comparison correction test (α < 5%).
Baseline: before hormone therapy; E2: estradiol only; E2+P estradiol +
micronized progesterone.
HDL-c high-density lipoprotein cholesterol, hsCRP high-sensitivity C-reactive
protein test, LDL-c low-density lipoprotein cholesterol, Total-c total lipoprotein
cholesterol; 2h glucose: glucose levels 2 hours after 75g oral glucose load.
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supporting the notion that micronized progesterone has
a neutral effect on intermediate surrogate variables of
cardiovascular risk [18]. Dansuk et al. [19] evaluated the
effects of five combinations of HT in postmenopausal
women, including E2 alone and E2 associated with medrox-
yprogesterone (E2+MPA), noretisterone (E2+NETA), dydro-
gesterone (E2+DG) and micronized progesterone (E2+P).
E2+NETA and E2+DG were found to improve insulin sensi-
tivity after 3 months of treatment, whereas E2+P or E2 alone
did not show such any effect in postmenopausal women.
It is well established that oral E2 therapy in conventional
doses induces an increase in hsCRP, while transdermal
E2 has either no effect on or even reduces hsCRP levels in
postmenopausal women [20]. Studies examining the effect
of progestins on markers of inflammation have produced
varying results [18]. In the present study there was no wor-
sening of hsCRP during HT with or without progesterone.
A limitation of this study is the short duration of treat-
ment (6 months or less), since in clinical practice patients
are usually treated for one year or more. Nevertheless,
previous studies have reported significant changes in lipids
and markers of endothelial function [21] after 4 to 12
weeks of HT. In addition, evidence suggests that there is a
“critical period” in the first months of HT, related to
greater inflammatory activation and higher thrombo-
embolic risk events. Further studies of longer duration will
be helpful to confirm our findings.Conclusions
Data from the present study suggest that the addition of
micronized progesterone to non-oral E2 did not induce
harmful effects on variables related to cardiovascular riskin a population of healthy, early postmenopausal women.
Micronized progesterone did not interfere with the
effects of non-oral E2, and did not abrogate the relief of
symptoms. Finally, combined micronized progesterone
and non-oral E2 treatment had neutral impact on blood




This study is nested within a crossover randomized
trial assessing the comparative effects of low-dose oral
HT and non-oral HT on cardiovascular risk factors
and markers of endothelial function in early postme-
nopausal women. Preliminary results of this trial
(which focused on the comparison between non-oral
estradiol-micronized progesterone or low-dose oral
estradiol-drospirenone therapy on metabolic variables
and markers of endothelial function in early postme-
nopause), including the first 40 women enrolled, have
been published [22].
In the present analysis, 42 women received 3 mg/day
17β estradiol by intranasal route (AerodiolW, Servier, RJ,
Brazil) for two months, and 53 received 1.5 mg/day 17β
estradiol gel by percutaneous route (OestrogelW,
Farmoquímica, SP, Brazil) for three months. Additionally,
both groups received 200 mg/day micronized progester-
one (UtrogestanW, Farmoquímica, SP, Brazil) together with
estrogen treatment by vaginal route 14 days/month during
the studied cycles (during 2 or three months, respectively).
The following were compared: effects of type of non-oral
estradiol (intranasal or percutaneous gel) before, during
the estradiol only portion of the study (E2) and during the
estradiol plus progesterone portion (E2+P). The effects of
E2 vs. E2+P for the overall group, regardless of route
(intranasal or percutaneous), were also analyzed.
The 95 women enrolled for this trial fulfilled the fol-
lowing inclusion criteria: 1) last menstrual period be-
tween 6 months and 3 years before the beginning of the
study plus follicle-stimulating hormone (FSH) levels
higher than 35 IU/L; 2) age between 42 and 58 years; 3)
no use of any medication known to interfere with hor-
monal, glucose or lipoprotein levels in the past 3
months; 4) no use of steroidal or non-steroidal anti-in-
flammatory drugs in the last 15 days. Patients presenting
diabetes, previous hysterectomy, endometrial thickness
higher than 0.5 cm, history of cancer, thromboembolism
or established CVD were excluded.
Nine patients dropped out in the first two months of
follow-up (Figure 1). Therefore, 86 patients completed
the study. Clinical evaluation was performed before the
treatment was begun and monthly during the trial. An-
thropometric measurements included body weight,
height, waist circumference (measured at the midpoint
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circumference (measured at the level of the greater tro-
chanter), waist-to-hip ratio (WHR), and BMI, current
measured weight in kg divided by height in m2). The
Kupperman score was assessed before and during
treatment. Blood pressure was measured twice, at a 1-
min interval in seated patients, using a digital sphyg-
momanometer (Omron HEM 742, Rio de Janeiro,
Brazil) with appropriate cuff for the arm diameter.
The study protocol was approved by the Ethics Com-
mittee at the Hospital de Clínicas de Porto Alegre, and
written informed consent was obtained from every sub-
ject (IRB 0000921/05-053). The study was registered at
clinicaltrials.gov (NCT01432028).Laboratory assessment
Blood samples were collected before treatment, during
the estradiol-only portion (E2) (days 12 to 14 of the sec-
ond treatment month), and at the end of treatment (days
24 to 28 of the last month of estradiol plus micronized
progesterone administration) (E2+P). All samples were
obtained between 08:00 and 10:00 a.m. After a 12-hour
overnight fast, blood samples were drawn from anFigure 1 Representation of the design. Flowchart showing the total numantecubital vein for determination of FSH, estradiol (E2),
lipid profile (total cholesterol, HDL-c and triglycerides)
plasma glucose (oral glucose tolerance test), and insulin.
Blood samples were also drawn for us-CRP.
Total cholesterol, HDL-c, triglycerides, and glucose
were determined by colorimetric-enzymatic methods
using the Bayer 1650 Advia System (Mannheim,
Germany). LDL-c was estimated indirectly using the for-
mula LDL = total cholesterol - HDL-c - triglycerides / 5.
Serum FSH was measured by electrochemilumines-
cence immunoassay (ECLIA), with intra and interassay
coefficients of variation (CV) of 1.8% and 3.3% for FSH.
The sensitivity of the assay was 0.05 IU/L for FSH. Estra-
diol was measured by ECLIA (Roche Diagnostics,
Mannheim, Germany), with an assay sensitivity of 5.0
pg/mL and intra and interassay CV of 5.7 and 6.4%.
Serum insulin levels were measured using ECLIA (Roche
Diagnostics, Mannheim, Germany), with sensitivity of
0.200 μIU/mL and intra and interassay CV of 2.0 and
4.3%, respectively. Ultra-sensitive CRP was assayed using
stored specimens, with a validated high-sensitivity
nephelometric method (Dade Behring Marburg,
Marburg, Germany). Sensitivity was 0.17 mg/L and intra
and interassay CV were 4.4 and 5.7%, respectively. Forber of patients enrolled, number of dropouts, and group description.
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tivity were considered as equal to 0.17 mg/L.
Statistical analysis
Results are expressed as means ± standard deviation
(SD) or median and interquartile range. Log10
transformation was used to normalize the distribu-
tion of non-Gaussian variables. Two-way analysis of
variance (ANOVA) with repeated measures was car-
ried out for comparing basal conditions, E2 and
E2+P. Bonferroni adjustment was used for multiple
comparisons. Friedman test was used for the ana-
lysis of Kupperman score, followed by the sign test.
All analyses were performed using the Statistical
Package for the Social Sciences (SPSS, Chicago, IL,
USA) and Stata (StataCorp LP, Texas, USA). Data
were considered to be significant at P < 0.05.
Abbreviations
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